## Background: Surveillance, epidemiology, and end results (seer) data for the years 1973-1992 documented that patients age < 50 years presented with more advanced disease. because of the increase in the incidence rate of lung adenocarcinoma in the past few decades and the presentation of more adva
Nasopharyngeal carcinoma in the young: A combined M.D. Anderson and Stanford experience
β Scribed by Leslye Ingersoll; Shiao Y. Woo; Sarah Donaldson; John Giesler; Moshe H. Maor; Don Goffinet; Ayten Cangir; Helmuth Goepfert; Mary Jane Oswald; Lester J. Peters
- Publisher
- Elsevier Science
- Year
- 1990
- Tongue
- English
- Weight
- 936 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0360-3016
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND. A previously published prospective randomized phase 3 trial showed that administration of 24 weeks of primary systemic chemotherapy (PST) with paclitaxel and FEC~75~ (fluorouracil, epirubicin, cyclophosphamide) concurrently with trastuzumab in patients with HER2βpositive
Background. The incidence of recurrent nasopharyngeal carcinoma (NPC) after primary radiotherapy is considerable. The result of re-irradiation to the recurrent tumor is not satisfactory. Methods. Thirty-one patients who received nasopharyngectomy for treatment of their recurrent nasopharyngeal carc
## Background: Small cell carcinoma of the esophagus is a rare disease with aggressive behavior and poor prognosis. multidrug chemotherapy remains the treatment of choice given the systemic nature of the disease. radiotherapy has been used concurrently with chemotherapy to enhance local control. th